Genentech-Pro: Product, Access, and Disease State Resources for Providers & Patients

Posted on 12/28/2024

View Resource

Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Posted on 11.11.2024

Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).
View Resource

ADC Cast is a Non-Promotional Educational Podcast Series Dedicated to Antibody Drug Conjugates (ADCs) in Breast Cancer

Posted on 10/16/2024

Hosted by Dr Javier Cortés and Prof. Peter Schmid, joined by an international panel of experts in ADCs and breast cancer, this educational podcast series unveils invaluable insights into ADCs, shedding light on their developmental history, their distinctive structural features and mechanisms of action, as well as potential future advancements.

Posted on 10/16/2024

Listen Here

Small Moments Can Help You Spot Endometrial Cancer

Posted on 08.12.2024

Too often, women with endometrial cancer (EC) have reported that their symptoms were stigmatized and dismissed. Even though diagnoses and deaths from this type of uterine cancer are on the rise, EC remains under-recognized.

Spot Her® is an initiative to help end the silence around EC and empower all people across generations and cultures to speak up, take action, and spot the potential signs at an early stage—when EC may be more treatable.
Learn More

What to Expect from Your Eye Care Appointments While Taking ELAHERE (mirvetuximab soravtansine-gynx)

Posted on 07.18.2024

This resource is intended for patients looking to:

• Understand what Ocular AEs may occur while on ELAHERE
• See what to expect during eye exams
• Review the important steps involved in proactively managing eye care while on treatment
• Learn the importance of communicating any side effects to your care team

Watch video

Best Practices for the Management of Ocular Adverse Events Associated with ELAHERE (mirvetuximab soravtansine-gynx)

Posted on 07.18.2024

This resource is intended for eye doctors or oncologists looking to:

• Understand why patients on ELAHERE require eye exams, and when
• Learn about what ocular AEs may be experienced by patients on ELAHERE
• Review the proactive eye drops administration patients should take during treatment
• See resources available to help facilitate communication between eye doctors and oncologists

Watch video

Help Patients Face the Realities of Life with Metastatic Breast Cancer Through Expose MBC

Published on: July 15, 2024

Gilead Oncology understands that metastatic breast cancer (MBC) is different from early breast cancer in many ways. Expose MBC is a platform for patients and their caregivers, friends, and family to share and gain honest information about their experiences, as well as to find resources, support, and community to help live their unique reality.

Visit http://Expose-MBC.com and share this site with your patients.

ESR1 Mutations in ER+/HER2 - Metastatic Breast Cancer

Published on: June 26, 2024

Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy.

Learn more about this ESR1 mutation at http://Knowesr1.com.

Diagnosis and Treatment of Hematologic Cancer

Published on: June 26, 2024

BPDCN is a cancer that affects your blood and the soft tissue inside your bones, which is called bone marrow. It can also affect other parts of your body, such as your lymph nodes, spleen, central nervous system, and skin.

Learn more about this hematologic disease at https://BPDCNinfo.com.

New Resources for Acute Myeloid Leukemia Care Providers

To improve outcomes for patients with acute myeloid leukemia, especially those who do not receive a transplant, the Association of Cancer Care Centers (ACCC), with support from Bristol Myers Squibb, has partnered with the HealthTree Foundation for Acute Myeloid Leukemia to develop a suite of resources, including:

• Cancer Buzz Podcast Series
• ACCC Buzz Educational Blog Series
• Comprehensive Effective Practices Guide

Access Resources Now